Candel Therapeutics, Inc. Common Stock (CADL) is a publicly traded Healthcare sector company. As of May 21, 2026, CADL trades at $8.00 with a market cap of $578.83M and a P/E ratio of -10.76. CADL moved +0.78% today. Year to date, CADL is +45.47%; over the trailing twelve months it is +30.46%. Its 52-week range spans $3.79 to $14.60. Analyst consensus is strong buy with an average price target of $21.17. Rallies surfaces CADL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Candel Therapeutics Grants 29,400 Options at $6.18 Under 2025 Plan: Candel Therapeutics granted 29,400 inducement stock options to two newly hired employees at a $6.18 exercise price under its 2025 Inducement Plan. Vesting provisions allocate 25% after one year and the remaining 75% in 36 equal monthly installments, contingent on continued service.
| Metric | Value |
|---|---|
| Price | $8.00 |
| Market Cap | $578.83M |
| P/E Ratio | -10.76 |
| EPS | $-0.72 |
| Dividend Yield | 0.00% |
| 52-Week High | $14.60 |
| 52-Week Low | $3.79 |
| Volume | 1.10K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-38.18M |
| Gross Margin | 0.00% |
6 analysts cover CADL: 0 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $21.17.